Market Overview

RBC Looks For Post-Approval Data On MannKind

Related MNKD
MannKind Is 'Making Progress' On Its Alternative To Mylan's EpiPen, Report Says
Mid-Afternoon Market Update: Dow Jumps Over 200 Points; SolarCity Shares Tumble
MannKind's Delisting Notice: Key Takeaways (Seeking Alpha)

Shares of MannKind (NASDAQ: MNKD) have traded up as much as 11 percent Monday, following Friday's announcement by the company that AFREZZA has received FDA approval.

In response to the announcement, RBC Capital released a note stating that the next key catalysts the firm sees are post-approval data and a partnership, which the firm views as "likely."

Shares of Mannking are currently trading at $11.01, up 10.1 percent.

Posted-In: RBC CapitalAnalyst Color News FDA


Related Articles (MNKD)

View Comments and Join the Discussion!